Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
131,900
Employees131,900
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
131,900
Employees131,900

JNJ Key Statistics

Market cap
386.71B
Market cap386.71B
Price-Earnings ratio
23.08
Price-Earnings ratio23.08
Dividend yield
3.01%
Dividend yield3.01%
Average volume
8.02M
Average volume8.02M
High today
$161.58
High today$161.58
Low today
$159.26
Low today$159.26
Open price
$159.64
Open price$159.64
Volume
8.34M
Volume8.34M
52 Week high
$175.97
52 Week high$175.97
52 Week low
$143.13
52 Week low$143.13

JNJ News

Simply Wall St 11h
Is Johnson & Johnson A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonym...

Is Johnson & Johnson A Risky Investment?
Seeking Alpha 21h
J&J talc bankruptcy plan appeal denied

An appellate court Thursday upheld a bankruptcy court's ruling from last year that denied Johnson & Johnson's (NYSE:JNJ) effort to use a subsidiary, LTL Managem...

J&J talc bankruptcy plan appeal denied
Benzinga 2d
How To Earn $100 Per Month From Johnson & Johnson Stock

How To Earn $100 Per Month From Johnson & Johnson Stock Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. J...

How To Earn $100 Per Month From Johnson & Johnson Stock

Analyst ratings

52%

of 23 ratings
Buy
47.8%
Hold
52.2%
Sell
0%

More JNJ News

Benzinga 3d
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression

Pharma giant Johnson & Johnson JNJ announced Monday it had asked the Food and Drug Administration (FDA) to approve its nasal spray as a monotherapy for treatmen...

Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Benzinga 4d
Achieve Financial Independence with This Dividend Stock in 10 Years

Achieve Financial Independence with This Dividend Stock in 10 Years Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the lin...

Achieve Financial Independence with This Dividend Stock in 10 Years
Quartz 4d
Johnson & Johnson says its ketamine-based drug can treat depression

Johnson & Johnson said on Monday that it submitted an application to the U.S. Food and Drug Administration (FDA) to expand the approved used of its ketamine-bas...

Johnson & Johnson says its ketamine-based drug can treat depression
Benzinga 4d
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate

Loading... Loading... Monday, Addex Therapeutics ADXN announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson JNJ, has discontinued the...

After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Benzinga 4d
Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle

Loading... Loading... Johnson & Johnson JNJ faced a legal setback on Friday when a New Jersey judge rejected its bid to disqualify the law firm Beasley Allen f...

Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle
Simply Wall St 7d
Possible Bearish Signals With Johnson & Johnson Insiders Disposing Stock

Over the past year, many Johnson & Johnson (NYSE:JNJ) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluatin...

Possible Bearish Signals With Johnson & Johnson Insiders Disposing Stock
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.